Announced that it has received CE Mark approval for its AeriSeal System today.

Aeris Therapeutics receives CE Tag approval for AeriSeal System to treat emphysema Aeris Therapeutics ( a company specializing in the development and commercialization of novel treatments for sufferers with emphysema and other advanced lung diseases, announced that it has received CE Mark approval for its AeriSeal System today. The AeriSeal System is designed to offer a safer nonsurgical alternative to lung volume decrease surgery, one of the few available treatments for sufferers with advanced emphysema. The CE Mark approval enables the Company to go forward with commercialization in Europe and other select marketplaces . David Dove, MD, President & CEO of Aeris Therapeutics commented, The attainment of the CE Mark represents the achievement of another significant milestone in Aeris’ mission to improve the lives of patients with advanced lung illnesses.

Aeras receives grant to build up new vaccines for TB TB vaccine development receives a boostThe Aeras Global TB Vaccine Foundation is very happy to announce that the Netherlands Ministry of Foreign Affairs has renewed its financing to Aeras with a pledge of an additional -11.7 million over four years to help expand its efforts to develop new vaccines to greatly help overcome the global epidemic of tuberculosis. This expression of support represents a continuation in the long-standing up collaboration between the Dutch government, Aeras and its research partners. This is the second grant to Aeras from the Netherlands Ministry of Foreign Affairs, representing a total dedication of -30.4 million to Aeras since 2006. ‘The forward motion of TB vaccine candidates in the development pipeline owes a great deal to the generous support of the Dutch Ministry of Foreign Affairs and the people of the Netherlands,’ said Jim Connolly, President and Chief Executive Officer of the Aeras Global TB Vaccine Foundation.